A detailed history of Schonfeld Strategic Advisors LLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 1,123,100 shares of STRO stock, worth $4.74 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,123,100
Previous 338,600 231.69%
Holding current value
$4.74 Million
Previous $1.45 Million 336.98%
% of portfolio
0.05%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.27 - $5.65 $2.57 Million - $4.43 Million
784,500 Added 231.69%
1,123,100 $6.35 Million
Q4 2023

Feb 14, 2024

SELL
$2.07 - $4.54 $33,948 - $74,456
-16,400 Reduced 4.62%
338,600 $1.45 Million
Q3 2023

Nov 14, 2023

SELL
$3.29 - $4.9 $4,277 - $6,370
-1,300 Reduced 0.36%
355,000 $1.23 Million
Q2 2023

Aug 14, 2023

BUY
$4.25 - $5.88 $43,792 - $60,587
10,304 Added 2.98%
356,300 $1.66 Million
Q1 2023

May 15, 2023

BUY
$4.48 - $8.45 $278,638 - $525,556
62,196 Added 21.92%
345,996 $1.6 Million
Q4 2022

Feb 14, 2023

BUY
$5.41 - $8.08 $1.28 Million - $1.91 Million
236,000 Added 493.72%
283,800 $2.29 Million
Q3 2022

Nov 14, 2022

SELL
$5.17 - $7.11 $90,475 - $124,425
-17,500 Reduced 26.8%
47,800 $265,000
Q2 2022

Aug 15, 2022

BUY
$3.41 - $8.95 $222,673 - $584,435
65,300 New
65,300 $340,000
Q2 2021

Aug 16, 2021

SELL
$18.03 - $23.82 $1.29 Million - $1.71 Million
-71,614 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$20.29 - $27.54 $1.33 Million - $1.81 Million
-65,613 Reduced 47.81%
71,614 $1.63 Million
Q4 2020

Feb 16, 2021

BUY
$10.16 - $23.98 $876,066 - $2.07 Million
86,227 Added 169.07%
137,227 $2.98 Million
Q3 2020

Nov 16, 2020

BUY
$7.44 - $13.15 $379,440 - $670,650
51,000 New
51,000 $1,000

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $220M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.